Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine
Antonio Gonzalez-Lopez, Jaap Oostendorp, Thomas Koernicke, Tommaso Fadini, Ugo D'Oro, Sherryl Baker, Derek T O'Hagan, Giuseppe Del Giudice, Emilio Siena, Oretta Finco, Duccio Medini, Antonio Gonzalez-Lopez, Jaap Oostendorp, Thomas Koernicke, Tommaso Fadini, Ugo D'Oro, Sherryl Baker, Derek T O'Hagan, Giuseppe Del Giudice, Emilio Siena, Oretta Finco, Duccio Medini
Abstract
An adjuvant system (AS37) has been developed containing a synthetic toll-like receptor agonist (TLR7a). We conducted a phase I randomized, observer-blind, dose-escalation study to assess the safety and immunogenicity of an investigational AS37-adjuvanted meningococcus C (MenC) conjugate vaccine in healthy adults (NCT02639351). A control group received a licensed MenC conjugate alum-adjuvanted vaccine. Eighty participants were randomized to receive one dose of control or investigational vaccine containing AS37 (TLR7a dose 12.5, 25, 50, 100 μg). All vaccines were well tolerated, apart from in the TLR7a 100 μg dose group, which had three reports (18.8%) of severe systemic adverse events. Four weeks after vaccination, human complement serum bactericidal assay seroresponse rates against MenC were 56-81% in all groups, and ELISA seroresponses were ≥81% for all AS37-adjuvanted vaccine groups (100% in 50 and 100 μg dose groups) and 88% in the control group. Antibody responses were maintained at six months after vaccination.
Copyright © 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Inc. All rights reserved.
Source: PubMed